CTSK and osteoporosis: Since newly developed agents for osteoporosis, such as antisclerostin antibody (Romosozumab) and the small molecule inhibitor of Cathepsin K (Odanacatib) show off-target cardiovascular and cerebrovascular events in clinical trials8,32, a bone-specific treatment strategy must be developed.